Tissue factor (TF) and tissue factor pathway inhibitor (TFPI) plasma levels in severe reeclampsia

被引：0
作者：
Godoi, L. C. [1 ]
Alpoim, P. N. [1 ]
Madeira, H. [2 ]
Petterson, J. [3 ]
Fernandes, A. P. [1 ]
Carvalho, M. G. [1 ]
Gomes, K. B. [1 ]
Dusse, L. M. S. [1 ]
机构：
[1] Univ Fed Minas Gerais, Fac Pharm, Dept Clin & Toxicol Anal, Belo Horizonte, MG, Brazil
[2] Maternidade Odete Valadares Belo Horizonte, Belo Horizonte, MG, Brazil
[3] Hosp Publ Reg Betim, Betim, MG, Brazil
来源：
THROMBOSIS RESEARCH | 2011年 / 127卷
关键词：
D O I：
10.1016/S0049-3848(11)70111-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S142 / S143
页数：2
相关论文
共 50 条
[21]   Evaluation of plasma tissue factor and tissue factor pathway inhibitor levels in childhood hemangiomas [J].
Turker, Meral ;
Irken, Gulersu ;
Oren, Hale ;
Yilmaz, Sebnem ;
Yuksel, Faize ;
Olgun, Nur .
PEDIATRIC BLOOD & CANCER, 2006, 47 (07) :914-917
[22]   Plasma free tissue factor pathway inhibitor (TFPI) levels and TF-induced thrombin generation ex vivo in men with low testosterone levels [J].
Agledahl, Ingvild ;
Brodin, Ellen ;
Svartberg, Johan ;
Hansen, John-Bjarne .
THROMBOSIS AND HAEMOSTASIS, 2009, 101 (03) :471-477
[23]   Measurement of plasma and platelet tissue factor pathway inhibitor (TFPI) in blood donors [J].
Ellery, P. ;
Augustsson, C. ;
Maroney, S. ;
Wood, J. ;
Peterson, L. ;
Hilden, I ;
Mast, A. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 :61-61
[24]   Heterogenous expression of TF (tissue factor) and tissue factor pathway inhibitors (TFPI, TFPI-2) in loco in different tumors. [J].
Sierko, E ;
Zimnoch, L ;
Kisiel, W ;
Wojtukiewicz, M .
BLOOD, 2003, 102 (11) :794A-794A
[25]   Genetic polymorphisms and plasma levels of tissue factor and tissue factor pathway inhibitor in venous thromboembolism [J].
Kwon, Aerin ;
Jo, Sang-Ho ;
Jo, Yun-A ;
Park, Ji-Young ;
Kim, Miyoung ;
Kang, Hee Jung ;
Kim, Han-Sung ;
Cho, Hyoun Chan ;
Lee, Young Kyung .
BLOOD COAGULATION & FIBRINOLYSIS, 2014, 25 (05) :416-421
[26]   Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation [J].
Shimura, M ;
Wada, H ;
Wakita, Y ;
Nakase, T ;
Hiyoyama, K ;
Nagaya, S ;
Mori, Y ;
Shiku, H .
AMERICAN JOURNAL OF HEMATOLOGY, 1997, 55 (04) :169-174
[27]   PLASMA TISSUE FACTOR AND TISSUE FACTOR PATHWAY INHIBITOR LEVELS IN PATIENTS WITH DISSEMINATED INTRAVASCULAR COAGULATION [J].
SHIMURA, M ;
WADA, H ;
WAKITA, Y ;
NAKASE, T ;
HIYOYAMA, K ;
NAGAYA, S ;
SHIKU, H .
THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) :1435-1435
[28]   Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation [J].
Shimura, M ;
Wada, H ;
Wakita, Y ;
Nakase, T ;
Hiyoyama, K ;
Nagaya, S ;
Mori, Y ;
Shiku, H .
AMERICAN JOURNAL OF HEMATOLOGY, 1996, 52 (03) :165-170
[29]   Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: Effect on TFPI activity [J].
Li, A ;
Wun, TC .
THROMBOSIS AND HAEMOSTASIS, 1998, 80 (03) :423-427
[30]   LEVELS OF MESSENGER-RNA CODING FOR TISSUE-FACTOR (TF) AND TISSUE-FACTOR COAGULATION INHIBITOR (TFPI) IN RESTING AND STIMULATED MONOCYTES [J].
FOSTER, S ;
MCGEE, MP .
FASEB JOURNAL, 1993, 7 (03) :A116-A116
12345